Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

No Thumbnail Available

Date

2022

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Citation

URI

http://hdl.handle.net/11727/8004

Collections

Tıp Fakültesi / Faculty of Medicine

Endorsement

Review

Supplemented By

Referenced By